CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 280 enrolled
Drug / intervention
ETI-204 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01929226
NCT01929226Phase 1Completed
CompareCT.gov

A Double-Blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Dose of ETI-204 in Adult Volunteers

Elusys Therapeutics·interventional·Posted Aug 27, 2013·Updated Apr 8, 2019

In Brief

A Phase 1 clinical trial evaluating ETI-204 and Placebo for Inhalational Anthrax. Completed, enrolled 280 participants across 1 site.

Detailed Summary

To evaluate the safety and tolerability and pharmacokinetics (PK) of a single intravenous (IV) dose of ETI-204 in adult volunteers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInhalational Anthrax
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 27, 2013
Enrollment StartJul 9, 2013
Primary CompletionNov 29, 2013
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 12.8 years ago

Interventions

ETI-204biological

Monoclonal Antibody

Placeboother

Placebo for ETI-204